$SLNO
SOLENO THERAPEUTICS INC

2023 Q1 Form 10-K Financial Statement

#000095017023009211 Filed on March 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.854M $2.402M $9.844M
YoY Change 7.98% -7.47% -8.9%
% of Gross Profit
Research & Development $5.316M $3.810M $15.27M
YoY Change 33.3% 2.04% -28.84%
% of Gross Profit
Depreciation & Amortization $490.0K $488.0K $20.00K
YoY Change -0.41% -0.81% 5.26%
% of Gross Profit
Operating Expenses $8.469M $5.610M $24.40M
YoY Change 46.7% 86.94% -22.62%
Operating Profit -$8.469M -$24.40M
YoY Change 46.7% -22.62%
Interest Expense $113.0K $125.0K $300.0K
YoY Change 413.64% 267.65% 172.73%
% of Operating Profit
Other Income/Expense, Net $113.0K -$1.000K $330.0K
YoY Change 130.61% -100.72% -35.04%
Pretax Income -$8.356M -$5.486M -$24.07M
YoY Change 45.98% 93.99% -22.14%
Income Tax
% Of Pretax Income
Net Earnings -$8.400M -$5.486M -$24.10M
YoY Change 46.75% 93.99% -22.01%
Net Earnings / Revenue
Basic Earnings Per Share -$0.88 -$2.87
Diluted Earnings Per Share -$0.88 -$0.65 -$2.87
COMMON SHARES
Basic Shares Outstanding 8.169M 8.159M 8.397M
Diluted Shares Outstanding 9.447M 8.397M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.874M $14.60M $14.60M
YoY Change -72.82% -31.46% -31.46%
Cash & Equivalents $7.900M $14.60M $14.60M
Short-Term Investments
Other Short-Term Assets $1.253M $1.045M $1.045M
YoY Change 24.8% -6.53% -6.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.127M $15.65M $15.65M
YoY Change -69.55% -30.22% -30.22%
LONG-TERM ASSETS
Property, Plant & Equipment $22.00K $26.00K $157.0K
YoY Change -94.16% -21.21% -65.42%
Goodwill
YoY Change
Intangibles $10.21M $10.69M
YoY Change -15.38%
Long-Term Investments
YoY Change
Other Assets $126.0K $0.00 $0.00
YoY Change 215.0% -100.0% -100.0%
Total Long-Term Assets $10.41M $10.85M $10.85M
YoY Change -17.19% -17.37% -17.37%
TOTAL ASSETS
Total Short-Term Assets $9.127M $15.65M $15.65M
Total Long-Term Assets $10.41M $10.85M $10.85M
Total Assets $19.54M $26.50M $26.50M
YoY Change -54.08% -25.47% -25.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.778M $1.777M $1.777M
YoY Change 15.22% -45.39% -45.39%
Accrued Expenses $4.291M $5.052M $5.052M
YoY Change -3.85% 14.04% 14.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.761M $7.313M $7.313M
YoY Change 6.13% -8.67% -8.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $9.135M $8.836M $8.836M
YoY Change 4.14% -9.4% -9.4%
Total Long-Term Liabilities $9.135M $8.836M $8.836M
YoY Change 4.14% -9.4% -9.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.761M $7.313M $7.313M
Total Long-Term Liabilities $9.135M $8.836M $8.836M
Total Liabilities $16.90M $16.15M $16.15M
YoY Change 5.04% -9.07% -9.07%
SHAREHOLDERS EQUITY
Retained Earnings -$245.8M -$237.4M
YoY Change 12.19% 11.27%
Common Stock $248.4M $247.8M
YoY Change 7.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.639M $10.35M $10.35M
YoY Change
Total Liabilities & Shareholders Equity $19.54M $26.50M $26.50M
YoY Change -54.08% -25.47% -25.47%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$8.400M -$5.486M -$24.10M
YoY Change 46.75% 93.99% -22.01%
Depreciation, Depletion And Amortization $490.0K $488.0K $20.00K
YoY Change -0.41% -0.81% 5.26%
Cash From Operating Activities -$6.700M -$5.143M -$20.80M
YoY Change 4.69% -25.06% -25.18%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $6.000K $13.00K
YoY Change -146.15% -159.09%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$6.000K -$13.00K
YoY Change -53.85% -40.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 14.09M
YoY Change -100.0% -100.0% -11109.38%
NET CHANGE
Cash From Operating Activities -6.700M -5.143M -20.80M
Cash From Investing Activities 0.000 -6.000K -13.00K
Cash From Financing Activities 0.000 0.000 14.09M
Net Change In Cash -6.728M -5.149M -6.702M
YoY Change -187.72% -25.17% -75.89%
FREE CASH FLOW
Cash From Operating Activities -$6.700M -$5.143M -$20.80M
Capital Expenditures $0.00 $6.000K $13.00K
Free Cash Flow -$6.700M -$5.149M -$20.81M
YoY Change 4.69% -24.83% -25.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001484565
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent
CY2022Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0666
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0666
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Registrant Name
EntityRegistrantName
SOLENO THERAPEUTICS INC
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-36593
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0523891
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
203 Redwood Shores Parkway
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 500
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
CY2022 dei City Area Code
CityAreaCode
650
CY2022 dei Local Phone Number
LocalPhoneNumber
213-8444
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2022 dei Trading Symbol
TradingSymbol
SLNO
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
7800000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8168788
CY2022 dei Auditor Name
AuditorName
Marcum LLP
CY2022 dei Auditor Location
AuditorLocation
San Francisco, CA
CY2022 dei Auditor Firm
AuditorFirmId
688
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14602000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21304000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1045000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1118000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
15647000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
22422000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
131000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
421000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10693000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12637000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
40000
CY2022Q4 us-gaap Assets
Assets
26497000
CY2021Q4 us-gaap Assets
Assets
35553000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1777000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3254000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1675000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
728000
CY2022Q4 slno Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
3222000
CY2021Q4 slno Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
3420000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
155000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
282000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
484000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
323000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7313000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8007000
CY2022Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
8835000
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
9547000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
175000
CY2022Q4 us-gaap Liabilities
Liabilities
16149000
CY2021Q4 us-gaap Liabilities
Liabilities
17760000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8159382
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8159382
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5324287
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5324287
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
80000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
247762000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
231068000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-237422000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213355000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10348000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
17793000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26497000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35553000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15265000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21453000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9844000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10806000
CY2022 slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
-712000
CY2021 slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
-731000
CY2022 us-gaap Operating Expenses
OperatingExpenses
24397000
CY2021 us-gaap Operating Expenses
OperatingExpenses
31528000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-24397000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-31528000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-30000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-508000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
300000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
110000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
330000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
618000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-24067000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-30910000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.87
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.87
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.81
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.81
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8397088
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8397088
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5318022
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5318022
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
45547000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3276000
CY2021 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
120000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-30910000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
17793000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2530000
CY2022 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
16000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
342000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-24067000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10348000
CY2022 us-gaap Profit Loss
ProfitLoss
-24067000
CY2021 us-gaap Profit Loss
ProfitLoss
-30910000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1964000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1963000
CY2022 slno Noncash Lease Expense
NoncashLeaseExpense
290000
CY2021 slno Noncash Lease Expense
NoncashLeaseExpense
288000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2530000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3276000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-30000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-508000
CY2022 slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
-712000
CY2021 slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
-731000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-113000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
139000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1477000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-235000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
947000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-277000
CY2022 slno Increase Decrease In Accrued Clinical Trial Site Costs
IncreaseDecreaseInAccruedClinicalTrialSiteCosts
-198000
CY2021 slno Increase Decrease In Accrued Clinical Trial Site Costs
IncreaseDecreaseInAccruedClinicalTrialSiteCosts
-369000
CY2022 slno Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-302000
CY2021 slno Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-263000
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
161000
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
135000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20781000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27770000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22000
CY2022 slno Proceeds From Sale Of Common Stock And Common Stock Warrants Net Of Costs
ProceedsFromSaleOfCommonStockAndCommonStockWarrantsNetOfCosts
15152000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1044000
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
16000
CY2021 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
120000
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
8000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14092000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-128000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6702000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27920000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21304000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49224000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14602000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21304000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
581000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-24100000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-237400000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14600000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20800000
CY2022Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-fifteen
CY2022Q3 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
110000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates in the financial statements include the valuation of deferred income tax assets, the valuation of financial instruments, stock-based compensation, accrued costs for services rendered in connection with third-party contactor clinical trial activities, and the valuation of contingent liabilities for the purchase price of assets obtained through acquisition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents at U.S. banking institutions, the majority of which are not covered by FDIC insurance. The Company maintains $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in its operating account at Silicon Valley Bank and subsequent to the year-end those amounts held in excess of the FDIC insurance limit were at risk as a result of SVB’s closure. On March 10, 2023, the FDIC took control of SVB, and the Federal Reserve announced that account holders would not suffer any loss on deposit balances above the FDIC insurance limit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33000
CY2022 us-gaap Depreciation
Depreciation
20000
CY2021 us-gaap Depreciation
Depreciation
19000
CY2022 slno Income Tax Reconciliation Change In Capital Losses
IncomeTaxReconciliationChangeInCapitalLosses
405000
CY2022 slno Income Tax Reconciliation Change In State Rates
IncomeTaxReconciliationChangeInStateRates
375000
CY2022 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-97000
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2342000
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
12000
CY2022 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P11Y
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5702000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8711000
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
652000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
364000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-734000
CY2022 slno Percentage Of Probability Of Achieving Milestone
PercentageOfProbabilityOfAchievingMilestone
0.72
CY2021 slno Percentage Of Probability Of Achieving Milestone
PercentageOfProbabilityOfAchievingMilestone
0.72
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
101000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
101000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
75000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
68000
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
1900000
CY2021 us-gaap Adjustment For Amortization
AdjustmentForAmortization
1900000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
200000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
300000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
200000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
324000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
316000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
6000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
29000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
24000
CY2022 slno Operating Lease Cost And Sublease Income
OperatingLeaseCostAndSubleaseIncome
353000
CY2021 slno Operating Lease Cost And Sublease Income
OperatingLeaseCostAndSubleaseIncome
346000
CY2021 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
4000
CY2021 slno Finance Lease Cost
FinanceLeaseCost
4000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
52000
CY2022 slno Income Tax Reconciliation Change In Fair Value Of Warrants
IncomeTaxReconciliationChangeInFairValueOfWarrants
-6000
CY2021 slno Income Tax Reconciliation Change In Fair Value Of Warrants
IncomeTaxReconciliationChangeInFairValueOfWarrants
-107000
CY2022 slno Income Tax Reconciliation Change In Fair Value Of Contingent Consideration
IncomeTaxReconciliationChangeInFairValueOfContingentConsideration
-150000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
354000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
277000
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
8000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
159000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
159000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
155000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y4M24D
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y4M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2021Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09
CY2021Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.09
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2500000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3300000
CY2021 slno Income Tax Reconciliation Change In Fair Value Of Contingent Consideration
IncomeTaxReconciliationChangeInFairValueOfContingentConsideration
-153000
CY2022 slno Income Tax Reconciliation Change In Net Operating Loss
IncomeTaxReconciliationChangeInNetOperatingLoss
-739000
CY2021 slno Income Tax Reconciliation Change In Net Operating Loss
IncomeTaxReconciliationChangeInNetOperatingLoss
-712000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2530000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3276000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.62
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
25.5
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-24173000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-30453000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
106000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-457000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24067000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30910000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5055000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6501000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-527000
CY2021 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-20000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
49024000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
48542000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4146000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3312000
CY2022Q4 slno Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
2828000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
547000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
573000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
44000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
59000
CY2022Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
555000
CY2021Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
1115000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2682000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1133000
CY2022Q4 slno Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
42000
CY2021Q4 slno Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
133000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
72000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
102000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
59940000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54969000
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2888000
CY2021Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
3536000
CY2022Q4 slno Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
35000
CY2021Q4 slno Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
118000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2923000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3654000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
57017000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
51315000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
57017000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51315000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5700000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1557000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1323000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
379000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
234000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1936000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1557000
CY2022Q4 slno Unrecognized Assets And Liabilities Related To Uncertain Tax Positions
UnrecognizedAssetsAndLiabilitiesRelatedToUncertainTaxPositions
1900000
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2022Q4 slno Unrecognized Tax Benefits Offset By Valuation Allowance
UnrecognizedTaxBenefitsOffsetByValuationAllowance
1900000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4747787
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
479565
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0

Files In Submission

Name View Source Status
0000950170-23-009211-index-headers.html Edgar Link pending
0000950170-23-009211-index.html Edgar Link pending
0000950170-23-009211.txt Edgar Link pending
0000950170-23-009211-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slno-20221231.htm Edgar Link pending
slno-20221231.xsd Edgar Link pending
slno-ex21_1.htm Edgar Link pending
slno-ex23_1.htm Edgar Link pending
slno-ex31_1.htm Edgar Link pending
slno-ex31_2.htm Edgar Link pending
slno-ex32_1.htm Edgar Link pending
slno-ex32_2.htm Edgar Link pending
slno-20221231_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
slno-20221231_def.xml Edgar Link unprocessable
slno-20221231_lab.xml Edgar Link unprocessable
slno-20221231_pre.xml Edgar Link unprocessable
slno-20221231_htm.xml Edgar Link completed